# language_name_wals:	English
# language_name_glotto:	English
# ISO_6393:	eng
# year_composed:	NA
# year_published:	NA
# mode:	written
# genre_broad:	technical
# genre_narrow:	NA
# writing_system:	Latn
# special_characters:	NA
# short_description:	EMEA
# source:	https://object.pouta.csc.fi/OPUS-EMEA/v3/raw/en.zip
# copyright_short:	http://opus.nlpl.eu/EMEA.php
# copyright_long:	http://opus.nlpl.eu/EMEA.php J. Tiedemann, 2012, Parallel Data, Tools and Interfaces in OPUS. In Proceedings of the 8th International Conference on Language Resources and Evaluation (LREC 2012)
# sample_type:	whole
# comments:	NA

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1/ 17 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Purevax RC
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substances:
Per 1-ml dose:
Freeze-dried pellet:
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)..................................... ≥ 104.9 CCID501 Inactivated feline Calicivirosis antigens (FCV 431 and G1 strains)............................. ≥ 2.0 ELISA U.
Excipient:
Gentamicin, at most..................................................................................................................... .16.5 µg Solvent:
Water for injections.................................................................................................................... q. s.
1 ml 1: cell culture infective dose 50% For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
4.
CLINICAL PARTICULARS
4.1 Target species
Cats.
4.2 Indications for use, specifying the target species
Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs and excretion.
Onsets of immunity have been demonstrated 1week after primary vaccination course for rhinotracheitis and calicivirus components.
The duration of immunity is 1 year after the last (re-)vaccination.
4.3 Contraindications
Do not use in pregnant animals.
The use is not recommended during lactation.
4.4 Special warnings
None.
4.5 Special precautions for use
Special precautions for use in animals
Use only in healthy animals.
2/ 17 Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
4.6 Adverse reactions (frequency and seriousness)
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).
A local reaction may occur (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most.
In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
4.7 Use during pregnancy, lactation or lay
Do not use in pregnant animals.
The use is not recommended during lactation
4.8 Interaction with other medicinal products and other forms of interaction
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine against feline leukaemia and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
4.9 Amounts to be administered and administration route
Inject by subcutaneous route one 1-ml dose of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination scheme:
Primary vaccination course:
- first injection: from 8 weeks of age,
- second injection:
3 to 4 weeks later.
In the presence of high levels of maternally derived specific antibodies, the primary vaccination course should be delayed until 12 weeks of age.
Revaccination: every year.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No effect other than those already mentioned in section “ Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.
4.11 Withdrawal period(s)
Not applicable.
5.
IMMUNOLOGICAL PROPERTIES
ATCvet code:
QI06AH08
Vaccine against feline viral rhinotracheitis and feline calicivirosis.
Stimulates active immunity against feline rhinotracheitis herpesvirus and feline calicivirus.
3/ 17 6.
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sucrose Sorbitol Dextran 40 Casein hydrolysate Collagen hydrolysate Salts
6.2 Incompatibilities
Do not mix with any other vaccine or immunological product, except those mentioned in section “ Interactions”.
6.3 Shelf life
18 months.
Use immediately after reconstitution
6.4 Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C) protected from light.
Do not freeze.
6.5 Nature and composition of immediate packaging
Type I glass bottle containing 1 dose of lyophilisate and type I glass bottle containing 1 ml of solvent, both closed with a butyl elastomer closure and sealed with an aluminium cap.
Pack containing 10 bottles of 1 dose of lyophilisate and 10 bottles of 1 ml of solvent Pack containing 50 bottles of 1 dose of lyophilisate and 50 bottles of 1 ml of solvent Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
7.
MARKETING AUTHORISATION HOLDER
MERIAL 29, avenue Tony Garnier 69007 LYON FRANCE
8.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 04/ 051/ 001-002
4/ 17 9.
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
23/ 02/ 2005
10.
DATE OF REVISION OF THE TEXT
17/ 02/ 2009
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
PROHIBITION OF SALE, SUPPLY AND/ OR USE
Not applicable.
5/ 17 ANNEX II
A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
D.
STATEMENT OF THE MRLs
6/ 17 A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer(s) of the biological active substance(s)
Merial Laboratory of Lyon Porte des Alpes Rue de l’ aviation 69800 SAINT-PRIEST France
Merial Laboratory of Lyon Gerland 254, Avenue Marcel Mérieux 69007 LYON France
Name and address of the manufacturer responsible for batch release
Merial Laboratory of Lyon Porte des Alpes Rue de l’ aviation 69800 SAINT-PRIEST France
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
To be supplied only on veterinary prescription.
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
Not applicable
D.
STATEMENT OF THE MRLs
Not applicable
7/ 17 ANNEX III
LABELLING AND PACKAGE LEAFLET
8/ 17 A.
LABELLING
9/ 17 PARTICULARS TO APPEAR ON THE OUTER PACKAGE {NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Purevax RC
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Per 1-ml dose:
FHV (F2 strain)................................................................................................................ ≥ 104.9 CCID50 FCV (431 and G1 strains).............................................................................................. ≥ 2.0 ELISA U.
Gentamicin, at most......................................................................................................................
16.5 µg
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
4.
PACKAGE SIZE
Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
5.
TARGET SPECIES
Cats.
6.
INDICATION(S)
Read the package leaflet before use.
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Subcutaneous use.
8.
WITHDRAWAL PERIOD
Not applicable.
9.
SPECIAL WARNING(S), IF NECESSARY
Read the package leaflet before use.
10/ 17 10.
EXPIRY DATE
EXP (mm/ yyyy) Use immediately after reconstitution.
11.
SPECIAL STORAGE CONDITIONS
Store and transport refrigerated (2 °C – 8 °C) protected from light.
Do not freeze.
12.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Read the package leaflet before use.
13.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
14.
THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
15.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MERIAL 29, avenue Tony Garnier F-69007 LYON FRANCE
16.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 04/ 051/ 001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/ 2/ 04/ 051/ 002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
17.
MANUFACTURER’ S BATCH NUMBER
Lot
11/ 17 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Purevax RC lyophilisate for injection
2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
Read the package leaflet before use
3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
1 dose
4.
ROUTE(S) OF ADMINISTRATION
Subcutaneous route
5.
WITHDRAWAL PERIOD
6.
BATCH NUMBER
Lot
7.
EXPIRY DATE
EXP (mm/ yyyy)
8.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
12/ 17 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Purevax RC solvent
2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
Read the package leaflet before use
3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
1 dose
4.
ROUTE(S) OF ADMINISTRATION
Subcutaneous route
5.
WITHDRAWAL PERIOD
6.
BATCH NUMBER
Lot
7.
EXPIRY DATE
EXP (mm/ yyyy)
8.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
13/ 17 B.
PACKAGE LEAFLET
14/ 17 PACKAGE LEAFLET
Purevax RC
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Marketing authorisation holder MERIAL 29, avenue Tony Garnier F-69007 Lyon France
Manufacturing authorisation holder responsible for batch release MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Purevax RC Lyophilisate and solvent for suspension for injection.
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Per 1-ml dose:
Freeze-dried pellet:
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)..................................... ≥ 104.9 CCID501 Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains).................... ≥ 2.0 ELISA U.
Excipient:
Gentamicin, at most..................................................................................................................... .16.5 µg Solvent:
Water for injection..................................................................................................................... q. s.
1 ml 1: cell culture infective dose 50%
4.
INDICATION(S)
Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs and excretion.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis and calicivirus components.
The duration of immunity is 1 year after the last (re-)vaccination.
5.
CONTRAINDICATIONS
Do not use in pregnant animals.
15/ 17 6.
ADVERSE REACTIONS
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).
A local reaction may occur (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most.
In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
7.
TARGET SPECIES
Cats.
8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Inject by subcutaneous route one 1-ml dose of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination scheme:
Primary vaccination course:
- first injection: from 8 weeks of age,
- second injection:
3 to 4 weeks later.
In the presence of high levels of maternally derived specific antibodies, the primary vaccination course should be delayed until 12 weeks of age.
Revaccination: every year.
9.
ADVICE ON CORRECT ADMINISTRATION
Use immediately after reconstitution.
Do not mix with any other vaccine or immunological product, except those mentioned below.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine against feline leukaemia and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
10.
WITHDRAWAL PERIOD
Not applicable.
11.
SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children.
Store and transport refrigerated (2 °C – 8 °C) protected from light.
Do not freeze.
16/ 17 12.
SPECIAL WARNING(S)
Use only in healthy animals.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Do not use in pregnant animals.
The use is not recommended during lactation.
No effect other than those already mentioned in section “ Adverse reactions” have been observed after the administration of several doses, except hyperthermia that may exceptionally last 5 days.
13.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
14.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
17/ 02/ 2009
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
15.
OTHER INFORMATION
Pack containing 10 bottles of 1 dose of lyophilisate and 10 bottles of 1 ml of solvent Pack containing 50 bottles of 1 dose of lyophilisate and 50 bottles of 1 ml of solvent Not all pack sizes may be marketed.
To be supplied only on veterinary prescription.
17/ 17